Yazdani Shahin, Hendi Kamran, Pakravan Mohammad
Ophthalmic Research Center and Department of Ophthalmology, Labbafinejad Medical Center, Shaheed Beheshti Medical University, Tehran, Iran.
J Glaucoma. 2007 Aug;16(5):437-9. doi: 10.1097/IJG.0b013e3180457c47.
Neovascular glaucoma is a secondary glaucoma with grave prognosis which follows ischemic retinal disorders in the majority of cases. Mediators that induce new vessel formation such as the vascular endothelial growth factor-A seem to play a key role in the pathophysiology of this condition. Herein, we report 2 cases with neovascular glaucoma secondary to ischemic central retinal vein occlusion who received treatment with intravitreal bevacizumab (Avastin) a nonselective antibody against vascular endothelial growth factor-A. Both patients demonstrated dramatic short-term response in terms of intraocular pressure reduction and regression of neovascularization.
新生血管性青光眼是一种预后严重的继发性青光眼，大多数情况下继发于缺血性视网膜疾病。诱导新血管形成的介质，如血管内皮生长因子-A，似乎在这种疾病的病理生理学中起关键作用。在此，我们报告2例继发于缺血性中央视网膜静脉阻塞的新生血管性青光眼患者，他们接受了玻璃体内注射贝伐单抗（阿瓦斯汀）治疗，这是一种针对血管内皮生长因子-A的非选择性抗体。两名患者在眼压降低和新生血管消退方面均表现出显著的短期反应。
